Journal of Infection
Volume 60, Issue 5 , Pages 371-381 , May 2010

Induction of balance and breadth in the immune response is beneficial for the control of SIVmac239 replication in rhesus monkeys

  • Caijun Sun

      Affiliations

    • Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences, Guangzhou 510530, China
    • Graduate School of Chinese Academy of Sciences, Beijing 100049, China
    • ,
  • Lei Zhang

      Affiliations

    • Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences, Guangzhou 510530, China
    • ,
  • Maochao Zhang

      Affiliations

    • Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences, Guangzhou 510530, China
    • ,
  • Yichu Liu

      Affiliations

    • Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences, Guangzhou 510530, China
    • ,
  • Miao Zhong

      Affiliations

    • Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences, Guangzhou 510530, China
    • Graduate School of Chinese Academy of Sciences, Beijing 100049, China
    • ,
  • Xin Ma

      Affiliations

    • Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences, Guangzhou 510530, China
    • ,
  • Ling Chen

      Affiliations

    • Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences, Guangzhou 510530, China
    • College of life science, University of science and technology of china (USTC), Hefei 230027, China
    • Corresponding Author InformationCorresponding author. Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences, 190 Kai Yuan Avenue, Science Park, Guangzhou 510530, China. Tel.: +86 20 32015295; fax: +86 20 32015299.

,Accepted 6 March 2010.

References 

  1. Moog C. Immune responses that correlate with HIV-1 protection?. AIDS. 2008;22(12):1461–1462
  2. Maness NJ, Yant LJ, Chung C, Loffredo JT, Friedrich TC, Piaskowski SM, et al. Comprehensive immunological evaluation reveals surprisingly few differences between elite controller and progressor Mamu-B*17-positive Simian immunodeficiency virus-infected rhesus macaques. J Virol. 2008;82(11):5245–5254
  3. Letvin NL, Rao SS, Dang V, Buzby AP, Korioth-Schmitz B, Dombagoda D, et al. No evidence for consistent virus-specific immunity in simian immunodeficiency virus-exposed, uninfected rhesus monkeys. J Virol. 2007;81(22):12368–12374
  4. Heeney JL, Plotkin SA. Immunological correlates of protection from HIV infection and disease. Nat Immunol. 2006;7(12):1281–1284
  5. Cohen J. AIDS vaccine trial produces disappointment and confusion. Science. 2003;299:1290–1291
  6. Cohen J. Promising AIDS vaccine's failure leaves field reeling. Science. 2007;318:28–29
  7. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature. 2008;455:613–619
  8. Benlahrech A, Harris J, Meiser A, Papagatsias T, Hornig J, Hayes P, et al. Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc Natl Acad Sci USA. 2009;106(47):19940–19945
  9. Hutnick NA, Carnathan DG, Dubey SA, Cox KS, Kierstead L, Ratcliffe SJ, et al. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+T cells. Nat Med. 2009;15(8):876–878
  10. O'Brien KL, Liu J, King SL, Sun YH, Schmitz JE, Lifton MA, et al. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans. Nat Med. 2009;15(8):873–875
  11. Perreau M, Pantaleo G, Kremer EJ. Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med. 2008;205(12):2717–2725
  12. Steinbrook R. One step forward, two steps back – will there ever be an AIDS vaccine?. N Engl J Med. 2007;357(26):2653–2655
  13. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med. 2008;14(6):617–621
  14. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002;415(6869):331–335
  15. Schell J, Rose NF, Fazo N, Marx PA, Hunter M, Ramsburg E, et al. Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. Vaccine. 2009;27(7):979–986
  16. Sealy R, Zhan X, Lockey TD, Martin L, Blanchard J, Traina-Dorge V, et al. SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development?. Curr HIV Res. 2009;7(5):497–503
  17. Ambrose Z, KewalRamani VN, Bieniasz PD, Hatziioannou T. HIV/AIDS: in search of an animal model. Trends Biotechnol. 2007;25(8):333–337
  18. Morgan C, Marthas M, Miller C, Duerr A, Cheng-Mayer C, Desrosiers R, et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med. 2008;5(8):e173
  19. Casimiro DR, Wang F, Schleif WA, Liang X, Zhang ZQ, Tobery TW, et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol. 2005;79(24):15547–15555
  20. Engram JC, Dunham RM, Makedonas G, Vanderford TH, Sumpter B, Klatt NR, et al. Vaccine-induced, Simian immunodeficiency virus-specific CD8+T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression. J Immunol. 2009;183(1):706–717
  21. Vogel TU, Reynolds MR, Fuller DH, Vielhuber K, Shipley T, Fuller JT, et al. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol. 2003;77(24):13348–13360
  22. Pal R, Venzon D, Letvin NL, Santra S, Montefiori DC, Miller NR, et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency. J Virol. 2002;76(1):292–302
  23. Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gómez-Román VR, Wang L, et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol. 2004;78(5):2112–2121
  24. Suh YS, Park KS, Sauermann U, Kim KS, Ahn SS, Franz M, et al. Prolonged survival of vaccinated macaques after oral SIVmac239 challenge regardless of viremia control in the chronic phase. Vaccine. 2008;26(51):6690–6698
  25. Casimiro DR, Cox K, Tang A, Sykes KJ, Feng M, Wang F, et al. Efficacy of multi-valent adenovirus-based vaccine against simian immunodeficiency virus challenge. J Virol. 2009 Dec 30;[Epub ahead of print]
  26. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8+T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007;13:46–53
  27. Casimiro DR, Tang A, Chen L, Fu TM, Evans RK, Davies ME, et al. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol. 2003;77:7663–7668
  28. Gorelick RJ, Benveniste RE, Lifson JD, Yovandich JL, Morton WR, Kuller L, et al. Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost. J Virol. 2000;74:11935–11949
  29. Lun WH, Takeda A, Nakamura H, Kano M, Mori K, Sata T, et al. Loss of virus-specific CD4(+) T cells with increases in viral loads in the chronic phase after vaccine-based partial control of primary simian immunodeficiency virus replication in macaques. J Gen Virol. 2004;85(Pt 7):1955–1963
  30. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science. 1992;258(5090):1938–1941
  31. Horton H, Vogel TU, Carter DK, Vielhuber K, Fuller DH, Shipley T, et al. Cellular immunity for prevention and clearance of HIV infection. Curr Mol Med. 2003;3:195–208
  32. Mansfield K, Lang SM, Gauduin MC, Sanford HB, Lifson JD, Johnson RP, et al. Vaccine protection by live, attenuated simian immunodeficiency virus in the absence of high-titer antibody responses and high-frequency cellular immune responses measurable in the periphery. J Virol. 2009;82(8):4135–4148
  33. Kong WP, Wu L, Wallstrom TC, Fischer W, Yang ZY, Ko SY, et al. Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol. 2009;83:2201–2215
  34. Johansson BE, Moran TM, Kilbourne ED. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc Natl Acad Sci USA. 1987;84:6869–6873
  35. Grifantini R, Finco O, Bartolini E, Draghi M, Del Giudice G, Kocken C, et al. Multi-plasmid DNA vaccination avoids antigenic competition and enhances immunogenicity of a poorly immunogenic plasmid. Eur J Immunol. 1998;28:1225–1232
  36. Maggiorella MT, Sernicola L, Crostarosa F, Belli R, Pavone-Cossut MR, Macchia I, et al. Multiprotein genetic vaccine in the SIV-Macaca animal model: a promising approach to generate sterilizing immunity to HIV infection. J Med Primatol. 2007;36:180–194
  37. Zhang ZQ, Fu TM, Casimiro DR, Davies ME, Liang X, Schleif WA, et al. Mamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection. J Virol. 2002;76(24):12845–12854
  38. Ma X, Tang LH, Qu LB, Ma J, Chen L. Identification of 17 novel major histocompatibility complex-A alleles in a population of Chinese-origin rhesus macaques. Tissue Antigens. 2009;73(2):184–187
  39. Vogel T, Norley S, Beer B, Kurth R. Rapid screening for Mamu-A1-positive rhesus macaques using a SIVmac Gag peptide-specific cytotoxic T-lymphocyte assay. Immunology. 1995;84(3):482–487
  40. Staprans SI, Barry AP, Silvestri G, Safrit JT, Kozyr N, Sumpter B, et al. Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci USA. 2004;101(35):13026–13031
  41. Barouch DH, Liu J, Lynch DM, O'Brien KL, La Porte A, Simmons NL, et al. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against SIV challenge in rhesus monkeys. J Virol. 2009;83(18):9584–9590
  42. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, et al. HIV preferentially infects HIV-specific CD4 + T cells. Nature. 2002;417(6884):95–98
  43. Grundner C, Pancera M, Kang JM, Koch M, Sodroski J, Wyatt R. Factors limiting the immunogenicity of HIV-1 gp120 envelope glycoproteins. Virology. 2004;330(1):233–248
  44. Gruber A, Chalmers AS, Rasmussen RA, Ong H, Popov S, Andersen J, et al. Dendritic cell-based vaccine strategy against human immunodeficiency virus clade C: skewing the immune response toward a helper T cell type 2 profile. Viral Immunol. 2007;20(1):160–169
  45. Wasik TJ, Jagodzinski PP, Hyjek EM, Wustner J, Trinchieri G, Lischner HW, et al. Diminished HIV-specific CTL activity is associated with lower type 1 and enhanced type 2 responses to HIV-specific peptides during perinatal HIV infection. J Immunol. 1997;158(12):6029–6036
  46. Spellberg B, Edwards JE. Type 1/type 2 immunity in infectious diseases. Clin Infect Dis. 2001;32:76–102

PII: S0163-4453(10)00073-3

doi: 10.1016/j.jinf.2010.03.005

Journal of Infection
Volume 60, Issue 5 , Pages 371-381 , May 2010

Article Tools

* Image Usage & Resolution